Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective

Pancreatic cancer has an annual incidence of 2/10,000 in Canada, with a one-year mortality rate greater than 80%. In the absence of a cost-effectiveness analysis in Canada, this study’s objective was to assess the cost-effectiveness of olaparib versus a placebo in adult patients with deleterious or...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzayeh Fashami, Fatemeh, Levine, Mitchell, Xie, Feng, Blackhouse, Gordon, Tarride, Jean-Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217075/
https://www.ncbi.nlm.nih.gov/pubmed/37232812
http://dx.doi.org/10.3390/curroncol30050354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217075/
https://www.ncbi.nlm.nih.gov/pubmed/37232812
http://dx.doi.org/10.3390/curroncol30050354

Ejemplares similares